Morphic Holding, Inc. (MORF)

37.22 -0.41 (-1.09%) At close: 04:00PM EDT

Morphic Holding, Inc.

35 Gatehouse Drive, A2
Waltham, MA 02451
United States
781 996 0955
https://www.morphictx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 103

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Praveen P. Tipirneni M.D.	CEO, MD & Director	969.01k	620.05k	1968
Dr. Bruce N. Rogers Ph.D.	Pres	659.9k	2.93M	1969
Dr. Timothy A. Springer Ph.D.	Founder, Independent Director & Member of Scientific Advisory Board	35k	N/A	1948
Dr. Marc Schegerin M.B.A., M.D.	CFO & COO	678.14k	1.9M	1976
Mr. William D. DeVaul Esq.	Gen. Counsel & Sec.	601.44k	4.32M	1971
Mr. Robert E. Farrell Jr., CPA, CPA	Sr. VP of Fin. & Operations and Chief Accounting Officer	N/A	N/A	1965
Dr. Blaise Lippa Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. Aaron Pelta	Sr. VP of Bus. & Corp. Devel.	N/A	N/A	N/A
Ms. Joanne Gibbons	Sr. VP of Regulatory Affairs	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Morphic Holding, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.